HCV Treatment
EASL 2015: Grazoprevir/ Elbasvir Is Highly Effective for Previously Untreated Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 27 April 2015 00:00
- Written by Keith Alcorn
A 12-week course of the combination of grazoprevir and elbasvir cured 95% of previously untreated people with hepatitis C virus gentoypes 1, 4, or 6, according to results of the C-EDGE trial presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last week in Vienna. However, the study also showed that people with higher baseline HCV viral load and genotype 1a may have a poorer response to this combination, particularly if they have naturally occurring HCV variants that are less sensitive to drugs from the NS5A inhibitor class.
EASL 2015: Grazoprevir/ Elbasvir Effective for Treatment-Experienced and HIV/HCV Coinfected Patients
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 27 April 2015 00:00
- Written by Keith Alcorn
The combination of grazoprevir and elbasvir without ribavirin is highly effective in curing hepatitis C virus infection in 12 weeks in some groups of treatment-experienced patients and in HIV/HCV coinfected people, and a 16-week course of treatment with ribavirin was highly effective even for the hardest-to-treat groups of treatment-experienced patients, according to 2 studies presented last week at the European Association for the Study of the Liver (EASL) 50th International Liver Congress this week in Vienna.
EASL 2015: Sofosbuvir + Daclatasvir + Ribavirin Cures Advanced Cirrhosis and Liver Transplant Patients
- Details
- Category: HCV Treatment
- Published on Sunday, 26 April 2015 00:00
- Written by Liz Highleyman
An interferon-free regimen of sofosbuvir, daclatasvir, and ribavirin for 12 weeks produced sustained response rates of 83% for hepatitis C patients with advanced liver cirrhosis and 94% for liver transplant recipients, with similar cure rates for those with hard-to-treat HCV genotype 3, according to findings from the ALLY-1 study presented at a late-breaker session at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last week in Vienna. More than half of patients with the most severe decompensated cirrhosis achieved sustained response.
EASL 2015: Sofosbuvir + Interferon/Ribavirin Effective for Hard-to-Treat Genotype 3 HCV Patients
- Details
- Category: HCV Treatment
- Published on Sunday, 26 April 2015 00:00
- Written by Liz Highleyman
A throwback regimen of sofosbuvir (Sovaldi), ribavirin, and pegylated interferon taken for 12 weeks cured 93% of patients with hepatitis C virus (HCV) genotype 3 -- substantially more than sofosbuvir plus ribavirin alone taken for 16 or 24 weeks, according to results from the BOSON study presented Saturday at the European Association for the Study of the Liver (EASL) 50th International Liver Congress in Vienna. Interferon-containing therapy for 3 months was described as "surprisingly well-tolerated."
EASL 2015: New European Guidelines Prioritize Interferon-Free Hepatitis C Treatment
- Details
- Category: HCV Treatment Guidelines
- Published on Friday, 24 April 2015 00:00
- Written by Liz Highleyman
The European Association for the Study of the Liver (EASL) released its latest hepatitis C treatment guidelines at the 50th International Liver Congress taking place this week in Vienna. The guidelines recommend a variety of interferon-free direct-acting antiviral (DAA) regimens for people with hepatitis C virus genotypes 1-6. The panel offered recommendations for patient groups that remain difficult to treat, such as those with decompensated cirrhosis, but noted that more research is still needed in several areas. Also concurrent with the conference, EASL and the Latin American Association for the Study of the Liver released joint guidelines for non-invasive assessment of liver disease severity, noting that liver stiffness measurement is becoming the standard of care.
More Articles...
- EASL 2015: Sofosbuvir/ Ledipasvir + Ribavirin Cures Most Hepatitis C Patients with Advanced Liver Disease
- EASL 2015: Merck Hepatitis C Combination Achieves 90% Cure in Advanced Cirrhosis Patients
- EASL 2015: Merck HCV Combination Effective after Failure of First Generation Direct-Acting Antivirals
- EASL 2015: International Liver Congress Now Underway in Vienna
Web Design and Development by